Patient Assessment

Complete all sections for the most accurate biologic recommendation.

🎯
Condition
Select the primary diagnosis
👤
Patient profile
Demographics and baseline characteristics
Relevant for ustekinumab, some biologics
Used to flag scoring limitations in skin of color
Type I
Always burns
Type II
Usually burns
Type III
Sometimes burns
Type IV
Rarely burns
Type V
Very rarely burns
Type VI
Never burns
◈
Skin of color — scoring note
PASI and EASI scores may underestimate disease severity in Fitzpatrick IV–VI. Erythema appears violaceous rather than red. Consider itch burden, sleep impact, and QoL metrics alongside visual scoring.
📊
Disease characteristics
Current disease burden and distribution
🔬
Comorbidities
Select all that apply — these directly affect biologic choice
✓
Psoriatic arthritis
Favors IL-17 / IL-23 agents
✓
Inflammatory bowel disease
Critical — affects IL-17 eligibility
✓
Cardiovascular disease
Favors IL-23 inhibitors
✓
Allergic asthma
Favors dupilumab (if AD)
✓
Recurrent serious infections
Caution with all biologics
✓
Demyelinating disease
Contraindicates TNF inhibitors
✓
Diabetes
Consider monitoring requirements
✓
Obesity (BMI >30)
Affects ustekinumab efficacy
✓
Pregnancy / planning pregnancy
Significantly affects biologic choice
✓
Prior or active malignancy
Caution with some agents
✓
Hepatitis B (active or prior)
Antiviral prophylaxis required
✓
TB exposure / latent TB
Must be treated before TNF inhibitors
Pregnancy status

Note: Certolizumab (Cimzia) is the preferred TNF inhibitor in pregnancy — does not cross placenta. For AD, dupilumab has the most reassuring registry data.

📋
Treatment history
Prior and current treatments
Add each biologic tried — drug and reason for stopping
⚙️
Practical factors
Access, preference, and adherence considerations
Oral options exist for some conditions (JAK inhibitors, TYK2 inhibitor)
✓
Applicable options
Updates live as you complete the form
Complete the form above — applicable biologics will appear here as you make selections.
Complete the form above to generate a personalized biologic recommendation with contraindication alerts and skin-of-color specific guidance.

For educational and training purposes only. Not a substitute for clinical judgment or institutional prescribing guidelines.